AU2016235495B2 - Deuterated analogs of etifoxine, their derivatives and uses therof - Google Patents

Deuterated analogs of etifoxine, their derivatives and uses therof Download PDF

Info

Publication number
AU2016235495B2
AU2016235495B2 AU2016235495A AU2016235495A AU2016235495B2 AU 2016235495 B2 AU2016235495 B2 AU 2016235495B2 AU 2016235495 A AU2016235495 A AU 2016235495A AU 2016235495 A AU2016235495 A AU 2016235495A AU 2016235495 B2 AU2016235495 B2 AU 2016235495B2
Authority
AU
Australia
Prior art keywords
compound
phenyl
chloro
amine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016235495A
Other languages
English (en)
Other versions
AU2016235495A1 (en
Inventor
Olivier Dasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaba Therapeutics Inc
Original Assignee
Gaba Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gaba Therapeutics Inc filed Critical Gaba Therapeutics Inc
Publication of AU2016235495A1 publication Critical patent/AU2016235495A1/en
Assigned to GABA THERAPEUTICS INC. reassignment GABA THERAPEUTICS INC. Request for Assignment Assignors: ANVYL, LLC
Priority to AU2020201728A priority Critical patent/AU2020201728B2/en
Application granted granted Critical
Publication of AU2016235495B2 publication Critical patent/AU2016235495B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2016235495A 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof Active AU2016235495B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020201728A AU2020201728B2 (en) 2015-03-20 2020-03-09 Deuterated analogs of etifoxine, their derivatives and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
US62/135,979 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020201728A Division AU2020201728B2 (en) 2015-03-20 2020-03-09 Deuterated analogs of etifoxine, their derivatives and uses thereof

Publications (2)

Publication Number Publication Date
AU2016235495A1 AU2016235495A1 (en) 2017-10-05
AU2016235495B2 true AU2016235495B2 (en) 2020-05-14

Family

ID=56977741

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016235495A Active AU2016235495B2 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof
AU2020201728A Active AU2020201728B2 (en) 2015-03-20 2020-03-09 Deuterated analogs of etifoxine, their derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020201728A Active AU2020201728B2 (en) 2015-03-20 2020-03-09 Deuterated analogs of etifoxine, their derivatives and uses thereof

Country Status (21)

Country Link
US (4) US10080755B2 (enExample)
EP (1) EP3347006B1 (enExample)
JP (3) JP6762507B2 (enExample)
KR (1) KR102290766B1 (enExample)
CN (1) CN107530323B (enExample)
AU (2) AU2016235495B2 (enExample)
BR (1) BR112017020081B1 (enExample)
CA (1) CA2979853C (enExample)
DK (1) DK3347006T3 (enExample)
ES (1) ES2928396T3 (enExample)
HR (1) HRP20221240T1 (enExample)
HU (1) HUE060240T2 (enExample)
IL (2) IL270627B2 (enExample)
LT (1) LT3347006T (enExample)
MX (1) MX383647B (enExample)
PL (1) PL3347006T3 (enExample)
PT (1) PT3347006T (enExample)
RS (1) RS63654B1 (enExample)
SI (1) SI3347006T1 (enExample)
SM (1) SMT202200407T1 (enExample)
WO (1) WO2016154039A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102290766B1 (ko) * 2015-03-20 2021-08-19 가바 테라퓨틱스, 아이엔씨. 에티폭신의 중수소화 유사체, 이의 유도체 및 그의 용도
US10420773B2 (en) * 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
AU2019239096A1 (en) * 2018-03-23 2020-08-27 Concert Pharmaceuticals, Inc. Deuterated analogs of D-beta-hydroxybutyric acid and uses thereof
CA3100716A1 (en) * 2018-05-18 2019-11-21 Ovid Therapeutics Inc. Methods of treating attention deficit hyperactivity disorder
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
KR20240050372A (ko) * 2021-09-14 2024-04-18 난징 미노바 파마슈티컬 컴퍼니, 리미티드 수용성 알로프레그나놀론 유도체 및 이의 제조 방법과 용도
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof
CN120390643A (zh) * 2022-10-24 2025-07-29 加巴疗法股份有限公司 艾替伏辛的氘代类似物及施用而没有代谢自身诱导的方法
WO2025085958A1 (en) * 2023-10-23 2025-05-01 Glomesh Intl Pty Ltd A module for mounting items

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167446A1 (en) * 2005-07-19 2007-07-19 Marc Verleye Neuroprotective compounds and pharmaceutical compositions comprising them

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
US20080039453A1 (en) * 2006-03-20 2008-02-14 David Putman Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
WO2007109289A1 (en) 2006-03-20 2007-09-27 Xytis Inc. Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
WO2013005753A1 (ja) * 2011-07-05 2013-01-10 公益財団法人乙卯研究所 重水素化フェニルプロピオン酸誘導体
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
KR102290766B1 (ko) * 2015-03-20 2021-08-19 가바 테라퓨틱스, 아이엔씨. 에티폭신의 중수소화 유사체, 이의 유도체 및 그의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070167446A1 (en) * 2005-07-19 2007-07-19 Marc Verleye Neuroprotective compounds and pharmaceutical compositions comprising them

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOSTER A B, ADVANCES IN DRUG RESEARCH, 1985, vol. 14, pages 1-40 *
YUN MI CHOI ET AL, THE KOREAN JOURNAL OF PAIN, 2015, vol. 28, no. 1, pages 4-10 *

Also Published As

Publication number Publication date
KR20170137085A (ko) 2017-12-12
US10736901B2 (en) 2020-08-11
JP2023009114A (ja) 2023-01-19
IL270627A (enExample) 2019-12-31
US11672805B2 (en) 2023-06-13
JP7376668B2 (ja) 2023-11-08
US20230263805A1 (en) 2023-08-24
HRP20221240T1 (hr) 2022-12-09
EP3347006A4 (en) 2019-04-24
PT3347006T (pt) 2022-10-17
SMT202200407T1 (it) 2022-11-18
US20190015419A1 (en) 2019-01-17
US20200405726A1 (en) 2020-12-31
AU2020201728B2 (en) 2021-12-23
CA2979853A1 (en) 2016-09-29
US20180064717A1 (en) 2018-03-08
CN107530323A (zh) 2018-01-02
EP3347006B1 (en) 2022-07-27
JP6762507B2 (ja) 2020-09-30
EP3347006A1 (en) 2018-07-18
US12433896B2 (en) 2025-10-07
AU2016235495A1 (en) 2017-10-05
PL3347006T3 (pl) 2022-11-14
JP2021001174A (ja) 2021-01-07
JP2018508592A (ja) 2018-03-29
CA2979853C (en) 2021-05-11
DK3347006T3 (da) 2022-10-17
IL270627B2 (en) 2023-03-01
BR112017020081A2 (pt) 2018-06-05
IL270627B (en) 2022-11-01
ES2928396T3 (es) 2022-11-17
LT3347006T (lt) 2022-10-25
RS63654B1 (sr) 2022-11-30
WO2016154039A1 (en) 2016-09-29
IL254567A0 (en) 2017-11-30
IL254567B (en) 2020-03-31
MX383647B (es) 2025-03-14
KR102290766B1 (ko) 2021-08-19
US10080755B2 (en) 2018-09-25
BR112017020081B1 (pt) 2021-11-30
AU2020201728A1 (en) 2020-03-26
MX2017011978A (es) 2018-02-09
HUE060240T2 (hu) 2023-02-28
SI3347006T1 (sl) 2022-11-30
CN107530323B (zh) 2021-05-04

Similar Documents

Publication Publication Date Title
US12433896B2 (en) Deuterated analogs of etifoxine, their derivatives and uses thereof
EP2571858B1 (en) Phenylmorpholines and analogues thereof
MXPA02002658A (es) Isomeros opticamente activos de ketotifeno y metabolitos terapeuticamente activos de los mismos.
US20080039453A1 (en) Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
US20080103154A1 (en) 3, 4-dihydro-2(IH)-quinolinone and 2(1H)-quinolinone derivatives
US8110569B2 (en) Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
US20240189316A1 (en) Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
JP7073272B2 (ja) 神経伝達物質放出剤としてのビニローグフェネチルアミン
HK1192877A1 (zh) 新的皮质多巴胺能-和nmda-受体介导的谷氨酸能神经传递调节剂
HK1192877B (en) Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GABA THERAPEUTICS INC.

Free format text: FORMER APPLICANT(S): ANVYL, LLC

FGA Letters patent sealed or granted (standard patent)